Pharmacokinetic Parameters of Quinine in Healthy Subjects and in Patients with Uncomplicated Malaria in Nigeria: Analysis of Data using a Population Approach
- PMID: 31871506
- PMCID: PMC6911901
- DOI: 10.1016/j.curtheres.2019.100567
Pharmacokinetic Parameters of Quinine in Healthy Subjects and in Patients with Uncomplicated Malaria in Nigeria: Analysis of Data using a Population Approach
Abstract
Background: The varied disposition of the antimalarial quinine partly explains its poor tolerance and toxicity in humans.
Objective: Using a population approach, the disposition of quinine in healthy subjects and patients with acute uncomplicated symptomatic malaria from Nigeria was re-examined with a view to providing population-specific attributes.
Methods: Concentration versus time profiles of quinine over 48 hours in healthy individuals, and over 7 days in malaria-infected patients, were stratified to reflect: concentration versus time data during the first 48 hours of quinine administration for healthy subjects and infected patients, concentration versus time data after 48 hours in infected patients, and all concentration versus time data available for healthy subjects and infected patients. Pharmacokinetic parameters were then estimated with a stochastic approximation expectation maximization algorithm.
Results: All datasets were fitted by a 1-compartment model with covariate contributions from body weight and infection status. The absorption rate constant, and volume of distribution and clearance were 1.72 h-1, 86.8 to 157.4 L, and 6.6 to 9.6 L/h, respectively. Infected patients experienced a 38% decrease in volume of distribution and a 31% decrease in clearance in the first 48 hours relative to healthy individuals. The contraction in volume of distribution and clearance diminished significantly after 48 hours of chronic quinine dosing in infected patients.
Conclusions: The study findings suggest that clinical interventions aimed at enhancing the safety and tolerance of quinine might be achieved by a rational decrease in dose size and/or dosing interval, post-48 hours of chronic quinine administration, in malaria-infected patients.
Keywords: Nigerians; malaria; population pharmacokinetics; quinine; tolerance; toxicity.
© 2019 The Author(s).
Conflict of interest statement
The authors have indicated that they have no conflicts of interest regarding the content of this article.
Figures


Similar articles
-
Disposition of oral quinine in African patients suffering from acute uncomplicated falciparum malaria.East Afr Med J. 1996 Aug;73(8):519-23. East Afr Med J. 1996. PMID: 8898467
-
Population pharmacokinetics of quinine in pregnant women with uncomplicated Plasmodium falciparum malaria in Uganda.J Antimicrob Chemother. 2014 Nov;69(11):3033-40. doi: 10.1093/jac/dku228. Epub 2014 Jun 25. J Antimicrob Chemother. 2014. PMID: 24970740 Free PMC article. Clinical Trial.
-
Population pharmacokinetic and pharmacodynamic properties of intramuscular quinine in Tanzanian children with severe Falciparum malaria.Antimicrob Agents Chemother. 2013 Feb;57(2):775-83. doi: 10.1128/AAC.01349-12. Epub 2012 Nov 26. Antimicrob Agents Chemother. 2013. PMID: 23183442 Free PMC article. Clinical Trial.
-
Clinical pharmacokinetics of antimalarial drugs.Clin Pharmacokinet. 1985 May-Jun;10(3):187-215. doi: 10.2165/00003088-198510030-00001. Clin Pharmacokinet. 1985. PMID: 3893840 Review.
-
Clinical pharmacokinetics of quinine and its relationship with treatment outcomes in children, pregnant women, and elderly patients, with uncomplicated and complicated malaria: a systematic review.Malar J. 2022 Feb 10;21(1):41. doi: 10.1186/s12936-022-04065-1. Malar J. 2022. PMID: 35144612 Free PMC article.
Cited by
-
Drug repurposing against SARS-CoV-1, SARS-CoV-2 and MERS-CoV.Future Microbiol. 2021 Nov;16:1341-1370. doi: 10.2217/fmb-2021-0019. Epub 2021 Nov 10. Future Microbiol. 2021. PMID: 34755538 Free PMC article.
-
Antimalarial drugs inhibit the replication of SARS-CoV-2: An in vitro evaluation.Travel Med Infect Dis. 2020 Sep-Oct;37:101873. doi: 10.1016/j.tmaid.2020.101873. Epub 2020 Sep 8. Travel Med Infect Dis. 2020. PMID: 32916297 Free PMC article.
-
Potential of Quinine Sulfate for COVID-19 Treatment and Its Safety Profile: Review.Clin Pharmacol. 2021 Dec 6;13:225-234. doi: 10.2147/CPAA.S331660. eCollection 2021. Clin Pharmacol. 2021. PMID: 34908881 Free PMC article. Review.
-
Endogenous Plant signals and human Health: Molecular mechanisms, ecological functions, and therapeutic Prospects.Biochem Biophys Rep. 2025 Jun 27;43:102114. doi: 10.1016/j.bbrep.2025.102114. eCollection 2025 Sep. Biochem Biophys Rep. 2025. PMID: 40678797 Free PMC article. Review.
-
Unlocking the Secrets of Nature: Phytochemicals as Key Players in Longevity and Healthy Aging.Cell Biochem Biophys. 2025 Aug 22. doi: 10.1007/s12013-025-01872-6. Online ahead of print. Cell Biochem Biophys. 2025. PMID: 40844700 Review. No abstract available.
References
-
- World Health Organisation . Third Edition. 2015. Guidelines for the treatment of malaria.
-
- Salako L.A., Sowunmi A. Disposition of quinine in plasma, red blood cells and saliva after oral and intravenous administration to healthy adult Africans. Eur J Clin Pharmacol. 1992;42(2):171–174. - PubMed
-
- Fuder H., Herzog R., Vaupel W., Wetzelsberger N., Lucker P.W. Study on the absolute bioavailability of quinine and theophylline from tablets after single dose oral administration as compared to intravenous infusion in healthy male non-smoking volunteers. Methods Find Exp Clin Pharmacol. 1994;16(9):651–660. - PubMed
LinkOut - more resources
Full Text Sources